At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Observer-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of a Varicella Vaccine at Various Potencies Compared With Varivax, as a First Dose, Administered in Healthy Children in Their Second Year of Life
In Brief
A Phase 2 clinical trial evaluating Investigational varicella vaccine low potency, Investigational varicella vaccine medium potency, and 6 other interventions for Chickenpox. Completed, enrolled 800 participants across 51 sites in 6 countries.
Detailed Summary
The purpose of this study is to assess immune response and safety of various potencies of an investigational chickenpox vaccine given to healthy children 12 to 15 months of age.
Study Details
Timeline
Interventions
1 dose of a low-potency investigational varicella vaccine administered subcutaneously.
1 dose of a medium-potency investigational varicella vaccine administered subcutaneously.
1 dose of a high-potency investigational varicella vaccine administered subcutaneously.
1 dose of a licensed varicella vaccine of Lot 1 administered subcutaneously.
1 dose of a licensed varicella vaccine of Lot 2 administered subcutaneously.
1 dose of a measles, mumps, and rubella vaccine administered subcutaneously.
1 dose of a hepatitis A vaccine administered intramuscularly.
1 dose of a 13-valent pneumococcal conjugate vaccine administered intramuscularly.